# Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

> **NCT03437668** · PHASE2,PHASE3 · TERMINATED · sponsor: **Chengappa, K.N. Roy, MD** · enrollment: 47 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** WSE
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03437668
- **Lead sponsor:** Chengappa, K.N. Roy, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-01
- **Primary completion:** 2023-06-12
- **Final completion:** 2023-06-12
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Unable to reach enrollment target due to COVID
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437668, "Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03437668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*